Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)
Crossref DOI link: https://0-doi-org.brum.beds.ac.uk/10.1186/s12885-017-3955-4
Published Online: 2018-01-03
Published Print: 2018-12
Update policy: https://0-doi-org.brum.beds.ac.uk/10.1007/springer_crossmark_policy
Huemer, Florian
Thaler, Josef
Piringer, Gudrun
Hackl, Hubert
Pleyer, Lisa
Hufnagl, Clemens
Weiss, Lukas
Greil, Richard
Funding for this research was provided by:
Arbeitsgemeinschaft Medikamentöse Tumortherapie
Province of Salzburg